Vitiligo Surgery (Melanocyte transplant)
Vitiligo is a common acquired depigmentation disorder of great cosmetic importance. The basic pathogenesis of vitiligo or for any of the putative subsets of vitiligo, still remains unknown. The medical treatment of vitiligo is dependent upon the presence of a melanocyte reservoir and is effective in only 60-70% of the patients. Certain types of vitiligo do not respond well to medical treatment and resistant lesions do persist even in those who respond. In light of these limitations of medical treatment, surgical treatment of vitiligo was first proposed in the 1960s. Over the years, the concept of surgical treatment has been expanded to include surgical "biotherapies" such as autologous, cultured melanocyte transplantation

Indications for Surgery and Patient Selection
Surgery is indicated for all types of stable vitiligo including segmental, generalized and acrofacial types that do not respond to medical treatment. While there is no consensus on definitive parameters for stability, various recommendations suggest a period of disease inactivity ranging from six months to two years.